Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
MEDIROM HEALTHCARE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
Di | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
18.02. | MEDIROM Healthcare sees FY24 revenue to be about JPY8.2B | 1 | Seeking Alpha | ||
18.02. | MEDIROM Healthcare Technologies Inc. Announces Preliminary, Unaudited Financial Results for Full Year 2024 Under Japanese GAAP | 93 | GlobeNewswire (Europe) | NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the "Company"), today announced its preliminary, unaudited... ► Artikel lesen | |
18.02. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
29.01. | MEDIROM Healthcare Technologies Inc. Announces December 2024 Key Performance Indicators (KPIs) | 1 | GlobeNewswire (USA) | ||
29.01. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
21.01. | MEDIROM Healthcare Technologies Inc.: Completion of Offering and Increase in Registered Capital | 1 | GlobeNewswire (USA) | ||
21.01. | MEDIROM Healthcare Technologies Inc.: MEDIROM MOTHER Labs Provides MOTHER Bracelet? Device and Remote Health Monitoring System, REMONY, to TOPPAN Inc. | 6 | GlobeNewswire (USA) | ||
21.01. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
23.12.24 | MEDIROM verzeichnet moderates Wachstum bei November-KPIs | 1 | Investing.com Deutsch | ||
23.12.24 | MEDIROM reports modest growth in November KPIs | 1 | Investing.com | ||
23.12.24 | MEDIROM Healthcare Technologies Inc. Announces November 2024 Key Performance Indicators (KPIs) | 2 | GlobeNewswire (USA) | ||
23.12.24 | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
13.12.24 | MEDIROM Healthcare Technologies Inc.: MEDIROM Healthcare Technology's Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round | 4 | GlobeNewswire (USA) | ||
13.12.24 | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
11.12.24 | MEDIROM Healthcare Technologies Inc. Announces Closing of Public Offering | 2 | GlobeNewswire (USA) | ||
11.12.24 | MEDIROM Healthcare Technologies Inc.: Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) | 2 | GlobeNewswire (USA) | ||
10.12.24 | MEDIROM Healthcare dips 8%, prices $5M ADS offering | 4 | Seeking Alpha | ||
10.12.24 | MEDIROM Healthcare Technologies Inc. Announces Pricing of Public Offering | 2 | GlobeNewswire (USA) | ||
09.12.24 | MEDIROM Healthcare Technologies Inc.: MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,120 | -4,01 % | Sernova Biotherapeutics Inc: Sernova arranges $1-million debenture financing | ||
ATOSSA THERAPEUTICS | 0,689 | -0,29 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 | SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
PING AN HEALTHCARE | 0,968 | -3,30 % | Ping An Healthcare and Technology Company Limited: Ping An Health Pioneers AI-Driven Healthcare with DeepSeek Integration | HONG KONG and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,019 | +8,05 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,442 | -1,34 % | Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance | The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/... ► Artikel lesen | |
CYTOSORBENTS | 0,923 | -11,93 % | Cytosorbents Corp - 8-K, Current Report | ||
VERU | 0,491 | +1,32 % | Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress | --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 0,747 | -1,32 % | Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif.... ► Artikel lesen | |
VOLITIONRX | 0,593 | 0,00 % | VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for
Friday, November 15 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., Nov. 14, 2024... ► Artikel lesen | |
EKSO BIONICS | 0,412 | +1,23 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results | SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
IMUNON | 0,820 | -0,61 % | Imunon, Inc.: IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study | IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in... ► Artikel lesen | |
BEYOND AIR | 0,264 | 0,00 % | Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update | Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international... ► Artikel lesen | |
AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
NOVACYT | 0,580 | -1,19 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights | ||
AROVELLA THERAPEUTICS | 0,067 | +5,51 % | AROVELLA THERAPEUTICS LIMITED: Top 20 Holders and Range of Units for Attaching Options |